MarketCap
Facebook
X
TelegramAnnual report 2023
added 02-07-2024
Deciphera Pharmaceuticals Gross Profit 2011-2026 | DCPH
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Quarterly Gross Profit Deciphera Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | 19.4 M | 15.4 M | 7.08 M | 62 K | - | - | 25 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 25 M | 62 K | 13.4 M |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K |  USA |
 |
AIkido Pharma
AIKI
|
10 K | - | 1.93 % | $ 17.4 M | USA |
 |
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
172 K | $ 2.92 | -3.16 % | $ 226 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
177 K | $ 3.17 | 3.0 % | $ 7.63 B |  Australia |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
371 M | $ 11.32 | 0.27 % | $ 732 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-523 K | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | USA |
 |
Ascendis Pharma A/S
ASND
|
319 M | $ 213.22 | -0.01 % | $ 5 B |  Danmark |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.03 M | $ 0.19 | -3.85 % | $ 413 M |  Israel |
 |
BioDelivery Sciences International
BDSI
|
14 M | - | -4.8 % | $ 255 M | USA |
 |
Athersys
ATHX
|
1.44 M | - | 3.77 % | $ 22.4 M | USA |
 |
Catalyst Biosciences
CBIO
|
109 M | $ 11.52 | -2.87 % | $ 758 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - |  Russia |
 |
Certara
CERT
|
129 M | $ 8.75 | -0.68 % | $ 1.4 B | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
500 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
53.8 M | - | -7.31 % | $ 87 M | USA |
 |
Acasti Pharma
ACST
|
-32.3 K | - | 4.01 % | $ 150 M |  Canada |
 |
Cellectis S.A.
CLLS
|
37.7 M | $ 4.81 | -0.62 % | $ 116 M |  France |
 |
Adaptimmune Therapeutics plc
ADAP
|
1.12 M | - | -15.15 % | $ 60.3 M | Britain |
 |
bluebird bio
BLUE
|
-4.03 M | - | - | $ 546 M | USA |
 |
Albireo Pharma
ALBO
|
39.2 M | - | -0.23 % | $ 916 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
374 M | $ 26.25 | -1.98 % | $ 1.27 B | USA |
 |
BeiGene, Ltd.
BGNE
|
3.22 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
103 M | $ 9.59 | -0.21 % | $ 141 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
301 M | $ 36.9 | 6.04 % | $ 3.81 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
319 K | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
1.27 M | - | 2.71 % | $ 14 M | USA |
 |
CorMedix
CRMD
|
61.7 K | $ 12.07 | 3.77 % | $ 614 M | USA |
 |
Axon Enterprise
AXON
|
1.24 B | $ 571.12 | 0.56 % | $ 43.3 B | USA |
 |
Celldex Therapeutics
CLDX
|
5.48 M | $ 26.95 | -0.79 % | $ 1.74 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
90 K | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
45.8 M | $ 2.6 | - | $ 16.3 M | USA |
 |
AstraZeneca PLC
AZN
|
43.9 B | $ 91.95 | 0.02 % | $ 96.9 B | Britain |
 |
Checkpoint Therapeutics
CKPT
|
1.07 | - | - | $ 169 M | USA |